AUSCANN GROUP HOLDINGS LTD (ASX:AC8) - Ann: Change of Director's Interest Notice - M. Washer, 37750843, page-12 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by dmaivn ↑

There is an article on the Internet from a research about how cannabis oils degenerate at temperature 4C. Every single bottle of medicines you see have labels telling about keeping at low temperature and away from light if it is glass. They die the glass very dark brown for that reason. If there is any way to keep the oils stable, it would have been published in the US and Canada (even without all the details). People would take the Canadian companies, US companies and other Australian companies as fools if there is a way to keep the oils stable but they don't use it. All cannabis oils on the market are either in bottles or in gel capsules simply because there is no other known way. No university research in the whole world has claimed to have found a way. No one would believe a claim from an Australian company without any research paper or product independently tested by a reputable university researcher or organisation.

Any way, fund managers will lose their job if they don't minimise the risk. When they sell to get out, they have done some due diligence. I have checked the IPO list for 2017 and 2018. All companies that have the share price gone under the IPO price have a similar pattern of behaviour. They made claims about product development ... without evidence to show the progress and no revenue to back it up.

Expand

The fact that no one has been able to solve this dilemma makes AusCann's following releases even more exciting I guess

"AusCann has completed a successful pilot study of an optimal final dose form for its proprietary cannabinoid medicines. New dose form solves the problem of stability of medical cannabis products currently on market. The study was carried out over the past ten months to be ready for the release of
AusCann’s first cannabinoid medicines in first half of 2019"

"AusCann has developed a unique effective stable oral dose form which provides consistent and stable dosages of the active cannabinoids with reliable bioavailability. AusCann has lodged a patent in respect to the intellectual property it has developed and will be used in the production of its first stage cannabinoid pharmaceuticals being released in first half of 2019."

"New proprietary solid hard shell capsules for treatment of chronic pain are scheduled for release in H1 2019. Australia’s leading wholesaler of pharmaceutical products, Australian Pharmaceutical Industries Limited (API) will manufacture AusCann’s hard shell capsules at its manufacturing facilities in Australia"

Sounds like a lot of work for a product you claim doesn't work just based on some internet articles you read?

The fact that no one has been able to solve this dilemma makes...